The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies
about
Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment.Cardio-renal protection with empagliflozin.The Use of Saxagliptin in People with Type 2 Diabetes in France: The Diapazon Epidemiological StudyCanagliflozin mediated dual inhibition of mitochondrial glutamate dehydrogenase and complex I: an off-target adverse effect.
P2860
The treatment of type 2 diabetes in the presence of renal impairment: what we should know about newer therapies
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
The treatment of type 2 diabet ...... uld know about newer therapies
@ast
The treatment of type 2 diabet ...... uld know about newer therapies
@en
The treatment of type 2 diabet ...... uld know about newer therapies
@nl
type
label
The treatment of type 2 diabet ...... uld know about newer therapies
@ast
The treatment of type 2 diabet ...... uld know about newer therapies
@en
The treatment of type 2 diabet ...... uld know about newer therapies
@nl
prefLabel
The treatment of type 2 diabet ...... uld know about newer therapies
@ast
The treatment of type 2 diabet ...... uld know about newer therapies
@en
The treatment of type 2 diabet ...... uld know about newer therapies
@nl
P2860
P3181
P356
P1476
The treatment of type 2 diabet ...... uld know about newer therapies
@en
P2093
Kamlesh Khunti
Sudesna Chatterjee
P2860
P3181
P356
10.2147/CPAA.S82008
P407
P577
2016-01-01T00:00:00Z